C
Cho Tang
Researcher at Pfizer
Publications - 20
Citations - 6717
Cho Tang is an academic researcher from Pfizer. The author has contributed to research in topics: Platelet-derived growth factor receptor & Tyrosine kinase. The author has an hindex of 16, co-authored 20 publications receiving 6524 citations. Previous affiliations of Cho Tang include New York University.
Papers
More filters
Journal Article
In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors Determination of a Pharmacokinetic/Pharmacodynamic Relationship
Dirk B. Mendel,A. Douglas Laird,Xiaohua Xin,Sharianne G. Louie,James G. Christensen,Guangmin Li,Randall E. Schreck,Tinya Abrams,Theresa J. Ngai,Leslie Lee,Lesley J. Murray,Jeremy P. Carver,Emily Chan,Katherine G. Moss,Joshua Ö. Haznedar,Juthamas Sukbuntherng,Robert A. Blake,Li Sun,Cho Tang,Todd W. Miller,Sheri Shirazian,Gerald Mcmahon,Julie M. Cherrington +22 more
TL;DR: The pharmacokinetic/pharmacodynamic relationship established for SU11248 in these preclinical studies has aided in the design, selection, and evaluation of dosing regimens being tested in human trials.
Journal ArticleDOI
Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors.
Moosa Mohammadi,Gerald McMahon,Li Sun,Cho Tang,Peter Hirth,Brian K. Yeh,Stevan R. Hubbard,Joseph Schlessinger +7 more
TL;DR: A new class of protein tyrosine kinase inhibitors was identified that is based on an oxindole core (indolinones) and two compounds from this class inhibited the kinase activity of fibroblast growth factor receptor 1 (FGFR1) and showed differential specificity toward other receptor tyrosin kinases.
Journal Article
SU5416 Is a Potent and Selective Inhibitor of the Vascular Endothelial Growth Factor Receptor (Flk-1/KDR) That Inhibits Tyrosine Kinase Catalysis, Tumor Vascularization, and Growth of Multiple Tumor Types
T. A. T. Fong,Laura K. Shawver,Li Sun,Cho Tang,H. App,T. J. Powell,Y. H. Kim,Randall E. Schreck,Xueyan Wang,Risau Werner,Axel Ullrich,K. P. Hirth,Gerald McMahon +12 more
TL;DR: Findings support that pharmacological inhibition of the enzymatic activity of the vascular endothelial growth factor receptor represents a novel strategy for limiting the growth of a wide variety of tumor types.
Journal Article
SU6668 Is a Potent Antiangiogenic and Antitumor Agent That Induces Regression of Established Tumors
A. Douglas Laird,Peter Vajkoczy,Laura K. Shawver,Andreas Thurnher,Congxin Liang,Moosa Mohammadi,Joseph Schlessinger,Axel Ullrich,Stevan R. Hubbard,Robert A. Blake,T. Annie T. Fong,Laurie M. Strawn,Li Sun,Cho Tang,Rachael E. Hawtin,Flora Tang,Narmada Shenoy,K. Peter Hirth,Gerald McMahon,Julie M. Cherrington +19 more
TL;DR: Oral or i.p. administration of SU6668 in athymic mice resulted in significant growth inhibition of a diverse panel of human tumor xenografts of glioma, melanoma, lung, colon, ovarian, and epidermoid origin, and intravital multifluorescence videomicroscopy of C6glioma xenografteds in the dorsal skinfold chamber model revealed thatSU6668 treatment suppressed tumor angiogenesis.
Journal ArticleDOI
Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases.
TL;DR: Structural-activity analysis supports the use of subsets of 3-substituted indolin-2-ones as specific chemical leads for the development of RTK-specific drugs with broad application for the treatment of human diseases.